Elanco Animal Health Inc. is among the companies taking a leading role in combating the re-emergence of deadly New World screwworm that was pushed out of the United States six decades ago.
Read More
The program will target investments in animal-health therapeutics and technologies but could also support other life sciences startups.
Read More
The Indianapolis-based company has announced the phased launch of Befrena, a monoclonal antibody injection for treating canine allergic and atopic dermatitis.
The settlement, which also involves several retailers, comes nearly two years after a complaint accused Elanco of monopolizing the market in violation of the federal Sherman Act and state antitrust lawsuits.
Demand for drugs to combat ticks and other pests was a major factor boosting Elanco Animal Health Inc.’s first quarter results, company executives said Wednesday.
Indiana’s largest life sciences companies and research universities are working to make the state an international leader in chemistry innovation — and they’re ready to launch the first step in a plan called Catalyze Indiana.
The Catalyst Scholars Fund is supported by a $69.4 million grant from Lilly Endowment Inc. to the CICP Foundation Inc. and matching commitments from participating universities.
Elanco Animal Health Inc. stock hit a 52-week high this week after the company posted double-digit revenue growth in the fourth quarter, driven by sales of some of its newest products.
BiomEdit CEO Aaron Schacht talks about the strategy behind the round and the changes the animal health startup had to make to secure the money it needed to bring its first product to market,
The Indianapolis-based company received U.S. regulatory approval last week for its second medicine in 18 months in what it describes as the $1.3 billion dog dermatology market.
An Elanco spokeswoman said cuts to the company’s Indiana workforce are “very minimal.” Most of the eliminated positions are from the company’s planned closure of its German R&D facility.
David Ricks, speaking Thursday during a panel at the annual BioCrossroads Life Sciences Summit, also called for Purdue and Indiana universities to upgrade their lab facilities.
Indianapolis-based Alloy Partners says its OneHealth Studio, a venture studio that quietly began operating last month in partnership with Elanco Animal Health Inc., will be ready to create its first startups early next year.
Despite reporting a loss, the company saw quarterly growth in the double digits and raised its full-year earnings estimate.
It took only a five-line clause in the state’s August land sale to Elanco Animal Health to bring down what was left of a nearly 100-year-old crane bay along the western bank of the White River.
Indiana’s growing partnership with Portugal includes imports like rubber, plastics and chemicals, the latter of which is driven largely by pharmaceuticals, according to a Portuguese trade representative.
As Elanco Animal Health Inc. settles into its new home in Indianapolis, leaders in Greenfield have turned their attention to the future of the company’s former corporate campus.
A demolition ended plans to turn the crane bay structure into an events pavilion that could host farmers markets, weddings, corporate gatherings and other activities.
Elanco opened the doors of its new headquarters at the former GM stamping plant site this week.
At Wednesday’s ribbon cutting, Elanco CEO Jeff Simmons said the new, three-building campus and developing OneHealth Innovation District “will write the history for the next 70 years of Elanco.”
The Indiana Economic Development Corp. approved $10 million in federal funding for the planned OneHealth Venture Studio, which will operate on Elanco Animal Health’s new Indianapolis campus.
“Water in Dripping, River” is a stainless steel artwork in Zheng Lu’s signature format that depicts splashes of water captured in midair.
